Catridecacog

Catridecacog (brand name Tretten in the US and NovoThirteen in Europe) is a class of recombinant factor XIII A-subunit based biopharmaceutical medicine, indicated in patients with a rare clotting disorder, congenital factor XIII A-subunit deficiency, which is a kind of Factor XIII deficiency. The medication prevents bleeding in patients with this condition, and has been approved by the U.S. Food and Drug Administration (FDA) for this use in the US in 2014. It was brought to market by Novo Nordisk.

单词	Catridecacog
释义	Catridecacog 英语百科 Catridecacog Catridecacog (brand name Tretten in the US and NovoThirteen in Europe) is a class of recombinant factor XIII A-subunit based biopharmaceutical medicine, indicated in patients with a rare clotting disorder, congenital factor XIII A-subunit deficiency, which is a kind of Factor XIII deficiency. The medication prevents bleeding in patients with this condition, and has been approved by the U.S. Food and Drug Administration (FDA) for this use in the US in 2014. It was brought to market by Novo Nordisk.
随便看	total condylar prosthesis total confinement system Total congenital impairment total conjugation total console total construction cost of water project total construction time total consumption burner total consumption expenditure total consumption of coal total consumption of general government total consumption of nuclear fuel total consumption of population total contact total contact fitting total contact prosthesis total contact ratio total contact roll length total contact sandal total contact socket total contact splint total contact walking cast total containment total content total content of CO2